In 1912, German physician Alfred Hauptmann reported that phenobarbital could reduce seizures in people with epilepsy. The discovery was important because it marked a major step away from bromide-era treatment and into modern antiseizure pharmacology.
A drug discovered through observation
Phenobarbital was already known as a sedative. Hauptmann noticed that patients given the drug also had fewer seizures. That observation led to its use as an antiseizure medicine and to one of the longest treatment histories in epilepsy.
Why it mattered
Phenobarbital showed that seizure control could be targeted pharmacologically. It became widely used because it was effective, inexpensive and relatively easy to produce. It also helped establish the idea that epilepsy treatment could be based on specific medicines rather than general sedation or institutional care alone.
The global story did not end in 1912
Phenobarbital later became part of international debates about cost, access and essential medicines. Its low price made it especially important in settings where newer antiseizure medicines were unavailable or unaffordable, even though sedation, cognitive effects and other adverse effects limited its appeal in some healthcare systems.
Sources
Yasiry & Shorvon — 100 years of phenobarbital therapy in epilepsy
Antiepileptic drug therapy: the story so far